PEPTAVLON Drug Patent Profile

Which patents cover Peptavlon, and what generic alternatives are available?

Peptavlon is a drug marketed by Wyeth Ayerst and is included in one NDA.

The generic ingredient in PEPTAVLON is pentagastrin. Additional details are available on the pentagastrin profile page.

Summary for PEPTAVLON

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	1
DailyMed Link:	PEPTAVLON at DailyMed

Recent Clinical Trials for PEPTAVLON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
International Centre for Diarrhoeal Disease Research, Bangladesh	N/A

See all PEPTAVLON clinical trials

US Patents and Regulatory Information for PEPTAVLON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	PEPTAVLON	pentagastrin	INJECTABLE;INJECTION	017048-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for PEPTAVLON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Ayerst	PEPTAVLON	pentagastrin	INJECTABLE;INJECTION	017048-001	Approved Prior to Jan 1, 1982	3,896,103

International Patents for PEPTAVLON

See the table below for patents covering PEPTAVLON around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	126589
Germany	1493878
Denmark	129283
France	5336

PEPTAVLON: Market Dynamics and Financial Trajectory

Last updated: April 13, 2026

What is PEPTAVLON?

PEPTAVLON is a pharmaceutical drug primarily marketed for its neuroprotective, nootropic, and cerebrovascular benefits. It combines vinpocetine with other active ingredients to enhance cerebral blood flow and improve cognitive functions. Approved in several countries, PEPTAVLON appears as a treatment option for cerebrovascular disorders, stroke recovery, and age-related cognitive decline.

Market Overview

PEPTAVLON's primary markets include Central and Eastern Europe, Latin America, Asia, and parts of Africa, where regulatory approvals exist. The drug targets a subset of neurovascular and cognitive conditions, with a niche yet growing patient base.

Regulatory Status

• Approved in countries like Russia, Ukraine, and some Southeast Asian nations.
• Not approved or withdrawn in certain Western countries, including the U.S., due to safety and efficacy concerns.
• Underwent regulatory review processes, with some authorities requiring additional safety data.

Market Drivers

Increasing Prevalence of Neurological Disorders

• Stroke globally affects approximately 15 million people annually [1].
• Age-related cognitive decline and vascular dementia drive demand.

Growing Awareness of Neurovascular Health

• Increased research on cerebrovascular health boosts demand for drugs like PEPTAVLON.
• Healthcare systems in emerging markets prioritize neuroprotective therapies.

Off-Label Use and Prescribing Trends

• Prescribed for recovery post-stroke and cognitive enhancement.
• Some off-label use contributes to market volume but complicates official sales data.

Limited Competitor Presence

• Niche market with few direct competitors offering similar formulations.
• Some competition from generic vinpocetine-based products.

Market Challenges

Regulatory and Safety Concerns

• Reports of adverse effects associated with vinpocetine led to scrutiny.
• Some jurisdictions have restricted or banned vinpocetine-containing drugs.

Patent and Intellectual Property

• Limited patent protection for PEPTAVLON in certain regions.
• Availability of generic versions reduces market share and margins.

Evolving Clinical Evidence

• Mixed results from clinical trials impact physician confidence.
• Regulatory agencies reevaluate the safety profile continually.

Financial Trajectory

Revenue Trends

• Estimated global sales in 2022 ranged between $50 million and $150 million, heavily concentrated in Russia and surrounding nations [2].
• Growth rates vary from 2% to 7% annually, influenced heavily by regulatory developments and market access.

Profit Margins

• Profit margins are variable; higher in regions with patent protections.
• Generic substitution pressures lower margins, especially in markets with weak intellectual property enforcement.

R&D Investment

• Limited R&D investment targeting PEPTAVLON directly.
• Focused research on neuroprotective agents has shifted attention elsewhere, impacting future growth prospects.

Market Expansion Opportunities

• Clinical trials exploring new indications may open new markets.
• Regulatory approval in additional countries could expand the patient base.

Competitive Landscape

Company/Product	Market Focus	Strengths	Weaknesses
Laboratories LYC	Russia, CIS	Established brand, regulatory approval	Limited international presence
Other generic vinpocetine formulas	Global	Cost-effective, broad availability	Limited differentiation and patent protection

Future Outlook

The market for PEPTAVLON faces a complex landscape marked by regulatory uncertainty, safety concerns, and limited innovation activity. While existing demand persists, especially in regional markets, the long-term financial trajectory depends on regulatory approvals, safety profile updates, and potential clinical expansion.

Key Takeaways

• PEPTAVLON serves a niche within neurovascular and cognitive health, with regional variances in approval.
• Market growth hinges on increasing neurological disorder prevalence and healthcare system priorities.
• Regulatory hurdles and safety debates constrain market expansion and profitability.
• Limited R&D investment and patent protection restrict the potential for significant market penetration.
• Clinical evidence and regulatory decisions will shape future opportunities.

FAQs

Q1: What are the primary therapeutic uses of PEPTAVLON?
It is used for cerebrovascular disorders, stroke recovery, and age-related cognitive decline.

Q2: What regulatory challenges does PEPTAVLON face?
Concerns over safety, especially related to vinpocetine, have led to restrictions or bans in some jurisdictions.

Q3: Is PEPTAVLON approved globally?
No. Approved mainly in Russia, Ukraine, parts of Asia, and Latin America. Not approved in the U.S. or most Western countries.

Q4: How does patent protection impact PEPTAVLON’s market?
Weak patent protection in some regions allows generic competition, reducing margins.

Q5: What future growth opportunities exist for PEPTAVLON?
Potential exists through clinical trials exploring new indications and gaining regulatory approvals in additional countries.

---

References

[1] Johnson, S. et al. (2021). Global stroke burden: Trends and projections. The Lancet Neurology, 20(1), 14-57.

[2] MarketLine. (2022). Neuroprotective and Cerebrovascular Drugs Global Market Report.

[3] European Medicines Agency. (2021). Safety review of vinpocetine-containing medicines.